{
    "Trade/Device Name(s)": [
        "Elecsys Tacrolimus"
    ],
    "Submitter Information": "Roche Diagnostics",
    "510(k) Number": "K173857",
    "Predicate Device Reference 510(k) Number(s)": [
        "K070820"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MLM"
    ],
    "Summary Letter Date": "October 23, 2018",
    "Summary Letter Received Date": "October 24, 2018",
    "Submission Date": "November 5, 2018",
    "Regulation Number(s)": [
        "21 CFR 862.1678"
    ],
    "Regulation Name(s)": [
        "Tacrolimus test system"
    ],
    "Analyte Class(es)": [
        "tdm",
        "transplant",
        "chemistry"
    ],
    "Analyte(s)": [
        "Tacrolimus"
    ],
    "Specimen Type(s)": [
        "Human whole blood"
    ],
    "Specimen Container(s)": [
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Elecsys",
        "cobas e immunoassay analyzers",
        "cobas e 411"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemiluminescent immunoassay (ECLIA)"
    ],
    "Methodologies": [
        "Immunoassay",
        "Competitive binding assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Roche Elecsys Tacrolimus electrochemiluminescent immunoassay for quantitative determination of tacrolimus in EDTA human whole blood",
    "Indications for Use Summary": "Aid in management of liver and kidney transplant patients receiving tacrolimus therapy by quantitative determination of tacrolimus in EDTA human whole blood using electrochemiluminescence immunoassay on Elecsys and cobas e analyzers",
    "fda_folder": "Clinical Chemistry"
}